Earnings results for Tandem Diabetes Care (NASDAQ:TNDM)
Tandem Diabetes Care, Inc. is expected* to report earnings on 02/24/2021 after market close. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.13. The reported EPS for the same quarter last year was $0.04.
Analyst Opinion on Tandem Diabetes Care (NASDAQ:TNDM)
13 Wall Street analysts have issued ratings and price targets for Tandem Diabetes Care in the last 12 months. Their average twelve-month price target is $117.62, predicting that the stock has a possible upside of 19.89%. The high price target for TNDM is $140.00 and the low price target for TNDM is $75.00. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Tandem Diabetes Care has received a consensus rating of Buy. The company’s average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings. According to analysts’ consensus price target of $117.62, Tandem Diabetes Care has a forecasted upside of 19.9% from its current price of $98.10. Tandem Diabetes Care has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Tandem Diabetes Care (NASDAQ:TNDM)
Tandem Diabetes Care does not currently pay a dividend. Tandem Diabetes Care does not have a long track record of dividend growth.
Insiders buying/selling: Tandem Diabetes Care (NASDAQ:TNDM)
In the past three months, Tandem Diabetes Care insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,038,067.00 in company stock. Only 6.00% of the stock of Tandem Diabetes Care is held by insiders. 88.60% of the stock of Tandem Diabetes Care is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Tandem Diabetes Care (NASDAQ:TNDM
Earnings for Tandem Diabetes Care are expected to grow in the coming year, from ($0.35) to ($0.03) per share. The P/E ratio of Tandem Diabetes Care is -121.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Tandem Diabetes Care is -121.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Tandem Diabetes Care has a P/B Ratio of 29.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here